February 22, 2016 – Partner Greg Sichenzia was quoted in a Law360 article titled “More Biotech IPOs Likely To Rely On Insiders Amid Slump.” The article discussed that more biotech companies are relying on support from inside investors to close deals due to weaker demand in the broader market. Greg noted that insider participation can be key to obtaining venture capital support.
Read the full article here.
